Breast Cancer Society Initiates Trial to Evaluate Efficacy of Denosumab at Increasing Bone Mass

A study group of the Japan Breast Cancer Society (JBCS) has initiated a multicenter trial to evaluate the efficacy of the anti-RANKL antibody denosumab at inhibiting the reduction in bone mass associated with hormone replacement therapy in post-menopausal patients with...read more